Didier Blaise Selected Research

Cyclophosphamide (Cytoxan)

10/2022	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2022	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
1/2022	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
1/2022	Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors.
1/2022	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
1/2022	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
1/2022	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
12/2021	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
1/2021	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
1/2021	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Didier Blaise Research Topics

Disease

103	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 08/2003
83	Leukemia 10/2022 - 08/2003
61	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 07/2003
44	Neoplasms (Cancer) 12/2021 - 07/2003
27	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 10/2003
23	Multiple Myeloma 06/2022 - 03/2008
19	Lymphoma (Lymphomas) 01/2022 - 05/2008
17	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 07/2012
16	Bronchiolitis Obliterans Syndrome 11/2021 - 11/2002
16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2021 - 07/2013
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2022 - 10/2002
11	Pathologic Complete Response 10/2022 - 05/2005
8	Hematologic Diseases (Blood Diseases) 01/2021 - 02/2012
8	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 07/2008
7	Residual Neoplasm 01/2020 - 10/2002
6	Primary Myelofibrosis (Myelosclerosis) 10/2021 - 01/2019
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 05/2007
4	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2021 - 11/2006
4	Infections 12/2021 - 01/2012
3	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 01/2016
3	Aplastic Anemia (Anemia, Hypoplastic) 01/2021 - 11/2015
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2019 - 12/2008
3	Disease Progression 01/2019 - 02/2013
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018 - 02/2013
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2021 - 01/2020
2	Sarcoma (Soft Tissue Sarcoma) 10/2020 - 04/2010
2	Monosomy 01/2020 - 01/2018
2	monosomy Chromosome 7 01/2020 - 01/2018
2	Communicable Diseases (Infectious Diseases) 07/2019 - 01/2016
2	Neurologic Manifestations (Neurological Manifestations) 10/2015 - 01/2012
2	Prolymphocytic Leukemia 08/2015 - 03/2015
2	Philadelphia Chromosome 04/2015 - 10/2002
2	Invasive Fungal Infections 01/2015 - 01/2010
2	Mycoses (Diseases, Fungus) 01/2015 - 01/2010
2	Sepsis (Septicemia) 08/2014 - 01/2008
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2010 - 06/2010
2	Ovarian Neoplasms (Ovarian Cancer) 09/2010 - 02/2002
1	Plasma Cell Leukemia 06/2022
1	Fever of Unknown Origin 01/2022
1	Fever (Fevers) 01/2022
1	Legionellosis 10/2021

Drug/Important Bio-Agent (IBA)

45	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 01/2015
25	Busulfan (Busulfex)FDA Link 01/2021 - 07/2003
23	fludarabineIBA 01/2021 - 07/2003
20	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 07/2003
7	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 05/2005
5	AntigensIBA 01/2022 - 06/2011
5	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 11/2016
5	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2021 - 01/2018
5	Rituximab (Mabthera)FDA Link 01/2020 - 09/2010
5	thymoglobulin FDA Link 11/2014 - 12/2010
4	Clofarabine (Clolar)FDA Link 08/2020 - 11/2016
4	LigandsIBA 01/2019 - 11/2009
4	Lenalidomide (CC 5013)FDA Link 11/2014 - 09/2010
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 12/2010
3	Interleukin-2 (IL2)IBA 01/2022 - 06/2011
3	CytokinesIBA 01/2022 - 12/2005
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 01/2021
3	treosulfanIBA 11/2021 - 08/2012
3	Brentuximab VedotinIBA 01/2019 - 12/2014
3	KIR ReceptorsIBA 01/2018 - 11/2009
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 12/2019
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 05/2015
2	idelalisibIBA 12/2021 - 12/2020
2	Calcineurin InhibitorsIBA 01/2021 - 12/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 01/2008
2	Chimeric Antigen ReceptorsIBA 01/2020 - 01/2020
2	Methotrexate (Mexate)FDA LinkGeneric 12/2019 - 10/2006
2	Sorafenib (BAY 43-9006)FDA Link 03/2019 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 01/2014
2	HLA-A Antigens (HLA-A)IBA 04/2017 - 08/2007
2	Azacitidine (5 Azacytidine)FDA Link 01/2016 - 07/2013
2	Daunorubicin (Cerubidine)FDA LinkGeneric 02/2015 - 05/2005
2	Bortezomib (Velcade)FDA Link 06/2008 - 03/2008
2	Imatinib Mesylate (Gleevec)FDA Link 09/2005 - 06/2004
1	Interferon-gamma (Interferon, gamma)IBA 01/2022
1	InterleukinsIBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022

Therapy/Procedure

125	Stem Cell Transplantation 06/2022 - 10/2002
118	Transplantation 10/2022 - 11/2002
66	Hematopoietic Stem Cell Transplantation 10/2022 - 01/2005
40	Cell Transplantation 06/2022 - 02/2015
36	Therapeutics 12/2021 - 10/2002
28	Haploidentical Transplantation 01/2022 - 12/2012
23	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
21	Homologous Transplantation 01/2022 - 07/2003
11	Bone Marrow Transplantation (Transplantation, Bone Marrow) 05/2019 - 05/2008
7	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 11/2004
6	Immunotherapy 06/2022 - 08/2003
6	Salvage Therapy 01/2022 - 10/2006
5	Autologous Transplantation 01/2018 - 01/2005
4	Induction Chemotherapy 01/2016 - 07/2004
3	Length of Stay 04/2020 - 01/2012
2	Artificial Respiration (Mechanical Ventilation) 10/2018 - 10/2015
2	Cell- and Tissue-Based Therapy (Cell Therapy) 06/2011 - 08/2003
1	Cord Blood Stem Cell Transplantation 10/2022